• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于经导管动脉化疗栓塞无效或不适用的不可切除肝细胞癌患者的三维适形放疗。

Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable.

作者信息

Kim Tae Hyun, Kim Dae Yong, Park Joong-Won, Kim Young Il, Kim Seong Hoon, Park Hong Suk, Lee Woo Jin, Park Sang Jae, Hong Eun Kyung, Kim Chang-Min

机构信息

Research Institute and Hospital, National Cancer Center, Goyang, Korea.

出版信息

Am J Clin Oncol. 2006 Dec;29(6):568-75. doi: 10.1097/01.coc.0000239147.60196.11.

DOI:10.1097/01.coc.0000239147.60196.11
PMID:17148993
Abstract

OBJECTIVES

To evaluate 3-dimensional conformal radiotherapy (3D-CRT) of unresectable hepatocellular carcinoma (HCC) patients for whom transcatheter arterial chemoembolization (TACE) was ineffective or unsuitable, and to determine whether tumor response and portal vein thrombosis (PVT) response to treatment were prognostic factors for overall survival.

METHODS

From July 2001 to June 2005, 70 unresectable HCC patients were treated with 3D-CRT; PVT was present in 41 patients. A daily radiation dose ranging from 2 to 3 Gy was administered using 6 or 15 MV x-rays to deliver a total dose between 44 and 54 Gy.

RESULTS

Of 70 patients, follow-up computed tomography showed that primary tumor responses were complete response (CR) in 4 (5.7%) patients, partial response (PR) in 34 (48.6%), no response (NR) in 28 (37.1%), and progressive disease (PD) in 4 (8.6%). Of 41 patients with PVT, PVT responses were CR in 4 (9.7%) patients, PR in 12 (29.3%), NR in 20 (48.8%), and PD in 5 (12.2%). The median survival times were 18.0 and 20.1 month in the primary tumor and the PVT responders (CR + PR), respectively, which were longer than the 6.8 and 7.2 months in the primary tumor and the PVT nonresponders (NR + PD), respectively.

CONCLUSIONS

3D-CRT was associated with a 54.3% objective response rate for primary tumors and a 39.0% objective response rate for PVT. Both primary tumor and PVT responses were found to be prognostic factors for overall survival. The present results suggest 3D-CRT is a practical treatment option in HCC patients for whom TACE is ineffective or unsuitable.

摘要

目的

评估经动脉化疗栓塞术(TACE)无效或不适用的不可切除肝细胞癌(HCC)患者的三维适形放疗(3D-CRT),并确定肿瘤反应和门静脉血栓形成(PVT)对治疗的反应是否为总生存的预后因素。

方法

2001年7月至2005年6月,70例不可切除的HCC患者接受了3D-CRT治疗;41例患者存在PVT。使用6或15MV X射线给予每日2至3Gy的放射剂量,总剂量为44至54Gy。

结果

70例患者中,随访计算机断层扫描显示,4例(5.7%)患者的原发性肿瘤反应为完全缓解(CR),34例(48.6%)为部分缓解(PR),28例(37.1%)无反应(NR),4例(8.6%)疾病进展(PD)。41例PVT患者中,4例(9.7%)患者的PVT反应为CR,12例(29.3%)为PR,20例(48.8%)为NR,5例(12.2%)为PD。原发性肿瘤和PVT反应者(CR+PR)的中位生存时间分别为18.0个月和20.1个月,分别长于原发性肿瘤和PVT无反应者(NR+PD)的6.8个月和7.2个月。

结论

3D-CRT对原发性肿瘤的客观缓解率为54.3%,对PVT的客观缓解率为39.0%。原发性肿瘤和PVT反应均被发现是总生存预后因素。目前结果表明,3D-CRT是TACE无效或不适用的HCC患者的一种实用治疗选择。

相似文献

1
Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable.对于经导管动脉化疗栓塞无效或不适用的不可切除肝细胞癌患者的三维适形放疗。
Am J Clin Oncol. 2006 Dec;29(6):568-75. doi: 10.1097/01.coc.0000239147.60196.11.
2
Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma.肝细胞癌门静脉血栓形成的三维适形放疗
Cancer. 2005 Jun 1;103(11):2419-26. doi: 10.1002/cncr.21043.
3
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.局部三维适形放疗联合经动脉化疗栓塞治疗Ⅲ期肝细胞癌患者的研究
Am J Clin Oncol. 2003 Aug;26(4):e92-9. doi: 10.1097/01.COC.0000077936.97997.AB.
4
[Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma].三维适形低分割单次大剂量放疗联合经动脉化疗栓塞治疗肝细胞癌门静脉癌栓的疗效
Ai Zheng. 2004 Jul;23(7):825-8.
5
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].三维适形放疗联合经动脉化疗栓塞治疗肝细胞癌
Zhonghua Zhong Liu Za Zhi. 2006 Mar;28(3):222-6.
6
Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma.肝细胞癌门静脉瘤栓的适形放射治疗
Radiother Oncol. 2007 Sep;84(3):266-71. doi: 10.1016/j.radonc.2007.07.005. Epub 2007 Aug 22.
7
Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy.采用立体定向放射治疗或三维适形放射治疗肝癌患者门静脉肿瘤血栓形成。
Jpn J Clin Oncol. 2006 Apr;36(4):212-7. doi: 10.1093/jjco/hyl006. Epub 2006 Apr 13.
8
Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization.伴有门静脉主干瘤栓的肝细胞癌:门静脉支架置入及经动脉化疗栓塞术后的三维适形放疗治疗
Cancer. 2009 Mar 15;115(6):1245-52. doi: 10.1002/cncr.24139.
9
Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus.经动脉化疗栓塞联合三维适形放疗治疗伴有下腔静脉癌栓的肝细胞癌。
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):180-7. doi: 10.1016/j.ijrobp.2009.07.1730. Epub 2009 Nov 18.
10
Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis.大剂量三维适形放疗治疗合并门静脉癌栓的肝细胞癌的疗效。
Jpn J Clin Oncol. 2012 Aug;42(8):721-9. doi: 10.1093/jjco/hys082. Epub 2012 Jun 11.

引用本文的文献

1
Efficacy and safety of image-guided hypofractionated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective, multicenter study.影像引导下大分割放疗治疗门静脉癌栓型肝细胞癌的疗效与安全性:一项回顾性多中心研究
BMC Cancer. 2025 Apr 21;25(1):736. doi: 10.1186/s12885-025-13739-3.
2
Microinvasion in hepatocellular carcinoma: predictive factor and application for definition of clinical target volume for radiotherapy.肝细胞癌的微侵袭:预测因素及其在放射治疗临床靶区定义中的应用。
World J Surg Oncol. 2024 May 8;22(1):125. doi: 10.1186/s12957-024-03399-1.
3
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
《2022年韩国肝脏癌协会-韩国国立癌症中心肝细胞癌管理实践指南》
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.
4
Effects of stereotactic body radiotherapy for clinical outcomes of patients with liver metastasis and hepatocellular carcinoma: A retrospective study.立体定向体部放疗对肝转移和肝细胞癌患者临床结局的影响:一项回顾性研究。
Oncol Lett. 2023 May 31;26(1):305. doi: 10.3892/ol.2023.13891. eCollection 2023 Jul.
5
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2022KLCA-NCC 韩国肝细胞癌管理实践指南。
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
6
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
7
Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis.大分割放疗用于缓解门静脉主干肿瘤血栓形成
Front Oncol. 2022 Apr 27;12:882272. doi: 10.3389/fonc.2022.882272. eCollection 2022.
8
Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.经动脉化疗栓塞术不完全治疗后肝细胞癌的挽救性外照射放疗:一项荟萃分析和系统评价
Medicina (Kaunas). 2021 Sep 22;57(10):1000. doi: 10.3390/medicina57101000.
9
Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes.肝细胞癌合并门静脉癌栓的先进放疗技术:可行性和临床结果。
PLoS One. 2021 Sep 23;16(9):e0257556. doi: 10.1371/journal.pone.0257556. eCollection 2021.
10
Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.阿昔替尼联合放疗治疗晚期肝细胞癌的 I 期临床试验。
Radiat Oncol. 2021 Jan 20;16(1):18. doi: 10.1186/s13014-020-01742-w.